CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 78 enrolled
Drug / intervention
EGT0001474 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00854113
NCT00854113Phase 1Completed
CompareCT.gov

A Phase I , Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of EGT0001474 In Healthy Volunteers

Theracos·interventional·Posted Mar 2, 2009·Updated Jun 6, 2019

In Brief

A Phase 1 clinical trial evaluating EGT0001474 and Placebo for Safety and Tolerability of EGT0001474 in Healthy Volunteers. Completed, enrolled 78 participants across 1 site.

Detailed Summary

This study evaluated the safety, tolerability and pharmacokinetics of single or multiple doses of EGT0001474.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSafety and Tolerability of EGT0001474 in Healthy Volunteers
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2, 2009
Enrollment StartFeb 1, 2009
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.3 years ago

Interventions

EGT0001474drug

Oral ascending doses given daily as capsules for up to 14 days

Placebodrug

Placebo to match EGT0001474